Wisdoflam-AQ Injection contains Diclofenac sodium at a concentration of 75 mg/ml, a nonsteroidal anti-inflammatory drug (NSAID) widely used for its potent analgesic, anti-inflammatory, and antipyretic properties. This injectable formulation is indicated for the management of acute musculoskeletal pain, postoperative pain, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and other inflammatory conditions where oral administration is not feasible or rapid onset of action is desired. Diclofenac exerts its therapeutic effects primarily by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of prostaglandins involved in pain, inflammation, and fever. Wisdoflam-AQ Injection is administered intramuscularly or intravenously under medical supervision, with dosage and duration tailored according to the severity of the condition and patient response. Caution is advised in patients with a history of gastrointestinal ulcers, bleeding disorders, renal or hepatic impairment, and cardiovascular diseases. Common adverse effects may include injection site pain, gastrointestinal discomfort, dizziness, and hypersensitivity reactions. Wisdoflam-AQ should be used with caution in pregnancy and lactation and is contraindicated in patients with known hypersensitivity to diclofenac or other NSAIDs. Proper monitoring and adherence to recommended dosing guidelines are essential to minimize potential risks and optimize therapeutic outcomes.